TGTX
TG Therapeutics, Inc.
$54.27
+7.34%
2026-08-21
About TG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Key Fundamentals
P/E Ratio
17.79
Forward P/E
16.44
EPS (TTM)
$2.74
ROE
100.3%
Revenue Growth (YoY)
70.3%
Profit Margin
55.2%
Debt/Equity
124.89
Price/Book
11.85
Beta
1.67
Market Cap
$7.46B
Avg Volume (10D)
2.5M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$59.30
60D Low
$36.47
Avg Volume
2.4M
Latest Close
$54.27
Get breakout alerts for TGTX
Sign up for Breakout Scanner to receive daily notifications when TGTX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
TG Therapeutics, Inc. (TGTX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors TGTX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. TGTX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.